东亚药业: 上海君澜律师事务所关于东亚药业2024年限制性股票激励计划回购注销部分限制性股票之法律意见书

Core Viewpoint - The legal opinion letter from Shanghai Junlan Law Firm confirms that Zhejiang Dongya Pharmaceutical Co., Ltd. has obtained the necessary approvals and followed the required procedures for the repurchase and cancellation of part of the restricted stock under its 2024 incentive plan, which will not significantly impact the company's financial status or operational results [1][8]. Group 1: Approval and Authorization - The company has passed resolutions regarding the 2024 restricted stock incentive plan and its implementation assessment management measures, as well as the authorization for the board of directors to handle related matters [5][6]. - The repurchase and cancellation of the restricted stock have been authorized by the shareholders' meeting, ensuring compliance with relevant regulations [5][8]. Group 2: Repurchase and Cancellation Details - The repurchase is due to one incentive object resigning and not meeting the incentive conditions, leading to the cancellation of 14,000 shares of restricted stock that had been granted but not yet released from restrictions [6][8]. - The repurchase price is set at 9.47 yuan per share, with adjustments to be made if there are changes in capital structure or stock distribution before the completion of the repurchase [6][8]. Group 3: Financial Impact and Disclosure - The funds for the repurchase will come from the company's own funds, and it is stated that this action will not have a significant impact on the company's financial condition or operational results [6][8]. - The company is required to disclose relevant information regarding the repurchase and cancellation in accordance with the management measures and incentive plan, ensuring transparency [6][8].